Kenvue Inc. (KVUE)

US — Consumer Defensive Sector
Peers:

Automate Your Wheel Strategy on KVUE

With Tiblio's Option Bot, you can configure your own wheel strategy including KVUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol KVUE
  • Rev/Share 7.8983
  • Book/Share 5.5973
  • PB 3.8304
  • Debt/Equity 0.8149
  • CurrentRatio 0.9776
  • ROIC 0.0756

 

  • MktCap 41144860800.0
  • FreeCF/Share 0.8519
  • PFCF 25.1959
  • PE 60.7995
  • Debt/Assets 0.3223
  • DivYield 0.0384
  • ROE 0.0658

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation KVUE Redburn Atlantic -- Neutral -- $23.5 April 10, 2025
Initiation KVUE Evercore ISI -- In-line -- $25 March 24, 2025
Upgrade KVUE Piper Sandler Neutral Overweight $21 $26 Jan. 6, 2025
Downgrade KVUE Deutsche Bank Buy Hold $25 $24 Dec. 12, 2024
Initiation KVUE Jefferies -- Buy -- $27 Sept. 24, 2024
Downgrade KVUE RBC Capital Mkts Outperform Sector Perform -- $24 Sept. 24, 2024

News

Two Stocks To Consider During Market Unrest To Provide Income Stability
BUD, JAPAY, JNJ, KVUE, MO, PM, XLF, XLK, XLP, XLV
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive

Investors should remain calm amid market volatility and consider buying during price dips, with 2025 expected to see more turbulence. Kenvue's strong brand portfolio and solid liquidity offer price stability and a 3.59% dividend yield, despite potential headwinds from tariffs and economic slowdown. Altria Group, with its 7% yield and Dividend King status, provides stability and potential upside during economic uncertainty, leveraging its pricing power and recession-proof products.

Read More
image for news Two Stocks To Consider During Market Unrest To Provide Income Stability
Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
KVUE
Published: February 21, 2025 by: The Motley Fool
Sentiment: Neutral

Kenvue (KVUE 0.54%) stock is down since completing its spin-off from Johnson & Johnson (JNJ 1.13%) in August 2023. But with more than a year of results now in the books, investors have had time to acclimate to Kenvue as an independent entity.

Read More
image for news Buy This Ultra-Safe High-Yield Dividend King Stock for Reliable Passive Income
Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
KVUE
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive

Kenvue, spun off from Johnson & Johnson, shows potential as a solid dividend stock post-2025 despite current economic challenges and recent earnings misses. The company boasts strong brands like Tylenol and Listerine, and management's cost-cutting initiatives aim to save $350 million by 2026. Kenvue's valuation and growth prospects make it attractive for long-term dividend investors, but cash flow headwinds warrant a hold rating for now.

Read More
image for news Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
KVUE
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference on Wednesday, February 19, 2025, at 3:00 p.m. Eastern Time. A live webcast of the presentation will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. i.

Read More
image for news Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference
Kenvue: An Intriguing Turnaround
KVUE
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Kenvue's stock has underperformed since its IPO, with disappointing guidance cuts for 2023 and 2024, and minimal growth projected for 2025. Despite recent struggles, Kenvue's strong brand portfolio, including Tylenol and Band-Aid, suggests potential for a turnaround, supported by activist investor Starboard Value. Execution issues, external factors, and potential structural changes have impacted Kenvue's performance, but improvements in marketing and management could drive future growth.

Read More
image for news Kenvue: An Intriguing Turnaround

About Kenvue Inc. (KVUE)

  • IPO Date 2023-05-04
  • Website https://www.kenvue.com
  • Industry Household & Personal Products
  • CEO Thibaut Mongon
  • Employees 22000

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.